Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease
NCT06329622
Atrophy, Chronic Disease
Shanghai, China
View Trial DetailsNCT Number: NCT00327860
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
Interested in participating?
Request Info6 month–22 year
All sexes
Observational
Children's Mercy Kansas City, Kansas City, Missouri, United States
Since its inception in 2003, the scientific aims of CKiD have been to determine the risk factors for decline in kidney function and to define how progressive decline in kidney function impacts biomarkers of risk factors for cardiovascular disease; neurocognitive function and behavior; and growth failure and its associated morbidity.
The goals have been extended to understand the impact of childhood CKD on: the risk factors for decline in kidney function in childhood and young adulthood; the development of cardiovascular disease in adolescence and young adulthood; the trajectories of markers of metabolic bone disease and the relationship to cardiovascular endpoints; and the social function, neurocognitive function and emotional well-being of adolescents and young adults and the relationship to successful transfer to adult nephrology care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Annually up to 5 years
The time to Kidney Replacement Therapy (KRT) is assessed as the date of diagnosis to the date of KRT. The exact KRT date is self-reported by the participant and confirmed by medical record abstraction.
Time frame: Up to 25 years
Define and identify novel and traditional risk factors for the accelerated decline of GFR at regular annual study visits.
Time frame: Up to 25 years
Analyze the association between decline in GFR and risk of progression of cardiovascular disease at regular annual study visits.
Contact information is provided by the study sponsor or research team.
Bradley Warady, MD
CONTACT
Susan Furth, MD, PhD
CONTACT
Johns Hopkins Bloomberg School of Public Health
Other
Acronym: CKiD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06329622
Atrophy, Chronic Disease
Shanghai, China
View Trial DetailsNCT07107945
Chronic Disease, Chronic Kidney Disease
Birmingham, Alabama, United States
View Trial DetailsNCT07153939
Arteriovenous Fistula, Arteriovenous Malformations
Dothan, Alabama, United States
View Trial DetailsNCT07729683
Chronic Disease, Chronic Kidney Disease
La Rochelle, France
View Trial Details